Connect your AI

Sonoco Products SON Finance Lease Right Of Use Asset Amortization

Finance Lease Right Of Use Asset Amortization at other companies

ConstelliumCSTM

$1.5M-14.3%

West Pharmaceutical ServicesWST

——

Other financials

Income statement

Revenue$1.7B-1.9%

Gross profit$345.6M-2.3%

Operating income$127.1M+0.2%

Net income$67.6M+24.2%

EPS (diluted)$0.68+23.6%

Balance sheet

Cash & equivalents$224.5M+17.1%

Total debt$6.3B-35.2%

Total equity$3.6B+45.8%

Total assets$11.1B-12.7%

Cash flow

Operating cash flow-$367.9M-76.8%

CapEx$62.1M-33.0%

Free cash flow-$430.0M-43.0%

Valuation

Market cap$5.01B+14.5%

Enterprise value$11.05B-19.5%

P/E4.9×-23.6×

P/S0.7×-0.1×

Profitability

Gross margin20.9%-0.5pp

Operating margin13.6%+6.9pp

Net margin13.6%+10.9pp

FCF margin2.9%+1.8pp

Returns & leverage

Return on equity33.8%+27.5pp

Debt / equity1.8×-2.2×

Current ratio1×+0.2×

Where this comes from

Reported directly by Sonoco Products in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAssetAmortization.

The official record: Sonoco Products’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sonoco Products's finance lease right of use asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Sonoco Products's finance lease right of use asset amortization?: Sonoco Products (SON) reported finance lease right of use asset amortization of $2.74M in Q1 2026.
How has Sonoco Products's finance lease right of use asset amortization changed year-over-year?: Sonoco Products's finance lease right of use asset amortization decreased by 8.9% year-over-year, from $3M to $2.74M.